Enclosed please find herewith Press Release of the Company for the fourth quarter and year ended March 31, 2026.
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences reported FY26 revenue of Rs. 25,518 Mn (6.9% YoY growth) and Q4FY26 revenue of Rs. 6,891 Mn (6.1% YoY growth). EBITDA grew 19.6% YoY to Rs. 8,577 Mn with margins at 33.6%, up 360 bps YoY, exceeding the guided 30-32% range. PAT grew 16.2% YoY to Rs. 5,645 Mn with margins at 22.1%. The company generated strong free cash flow of Rs. 2,590 Mn, ending with cash of Rs. 7,824 Mn and a debt-free balance sheet. The CDMO business delivered turnaround with 18% YoY growth in H2, while GPL business de-grew 4.9%. Management guided for FY27 high single-digit revenue growth with margins sustained above 30%.
Strong operational performance with margin expansion above guidance signals operational efficiency. The cash-rich, debt-free balance sheet provides flexibility for growth investments. Growth guidance for FY27 indicates sustained positive momentum.